Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Character Group withdraws FY guidance on tariff uncertainty

(Sharecast News) - Toys company Character Group withdrew its FY guidance on Friday as a result of Donald Trump's recently imposed "reciprocal" tariffs. Character said recent unilateral tariffs imposed on imports into the USA and escalating retaliatory measures had "greatly impacted" global economic stability in a very short space of time and forced it to reassess FY sales guidance.

Character said visibility for forecasting sales to USA, which accounted for roughly 20% of group turnover in the last financial year, and its ability to assess the financial implications have been "considerably obscured by these events".

"Consequently, the effect of the imposition of the trade tariffs will be felt in the second half by the group and, as a result, the company is withdrawing the market guidance for the year ending 31 August 2025," said Character.

However, despite this, Character said it "remains confident" that it will be profitable for the current financial year as a whole.

As far as its H1 results were concerned, Character stated that "all indications at this time" were that results will be in line with H124, in which it delivered a pre-tax profit of £2.1m.

"The company continues to have a strong balance sheet with healthy cash balances and the Board is confident that it can ride out this storm," it added.

As of 1010 BST, Character shares were down 6.59% to 241.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.